In vitro evaluation of voriconazole against some clinically important fungi | Zendy

Michael R. McGinnis | Zendy; L Pasarell | Zendy; Deanna A. Sutton | Zendy; Annette W. Fothergill | Zendy; Chester R. Cooper | Zendy; Michael G. Rinaldi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In vitro evaluation of voriconazole against some clinically important fungi

Author(s) -

Michael R. McGinnis,

L Pasarell,

Deanna A. Sutton,

Annette W. Fothergill,

Chester R. Cooper,

Michael G. Rinaldi

Publication year - 1997

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.41.8.1832

Subject(s) - voriconazole , itraconazole , fluconazole , amphotericin b , dimorphic fungus , microbiology and biotechnology , terbinafine , medicine , biology , antifungal , pharmacology , yeast , genetics

Voriconazole was compared to amphotericin B, fluconazole, and itraconazole by using an in vitro macrobroth dilution test based upon current National Committee for Clinical Laboratory Standards tentative standards against the dimorphic fungi and several opportunistic molds and yeasts. In all instances, the voriconazole MICs were lower than those of fluconazole. In most instances, the MICs were lower than the recorded MICs of amphotericin B and itraconazole.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research